No. of 177Lu-PSMA cycles | Best % PSA decline | PSA progression-free survival* (d) | ||||
Patient no. | Initial | Retreatment | Initial | Retreatment | Initial | Retreatment |
2 | 4 | 2 | 39 | 60 | 485 | 106 |
3 | 4 | 2 | 94 | 64 | 249 | 75 |
5 | 2 | 3 | 99 | 80 | 248 | 259 |
7 | 4 | 3 | 92 | 54 | 538 | 132 |
18 | 3 | 3 | 100 | 98 | 566 | 432 |
22 | 4 | 2 | 89 | 70 | 314 | 90 |
23 | 4 | 5 | 97 | 63 | 469 | 291 |
24 | 4 | 1 | 15 | No response | 266 | No response |
29 | 4 | 1 | 100 | 85 | 929 | In follow-up |
32 | 4 | 1 | 50 | No response | 245 | No response |
34 | 4 | 2 | 100 | No response | 273 | No response |
35 | 4 | 4 | 99 | 98 | 296 | 237 |
38 | 2 | 3 | 100 | 98 | 293 | 179 |
44 | 4 | 1 | 91 | 73 | 302 | 123 |
45 | 4 | 1 | 69 | No response | 484 | No response |
↵* “Initial” measured from date of first treatment to PSA nadir, and “Retreatment” measured from date of treatment to PSA nadir.